{"entity": "publication", "iuid": "99bb1d71772a4e929093337f10d3a44d", "timestamp": "2026-11-20T19:44:29.420Z", "links": {"self": {"href": "https://publications.scilifelab.se/publication/99bb1d71772a4e929093337f10d3a44d.json"}, "display": {"href": "https://publications.scilifelab.se/publication/99bb1d71772a4e929093337f10d3a44d"}}, "title": "Clinical, radiological, and biomarker outcomes following a switch from MabThera\u00ae to the rituximab biosimilar Rixathon\u00ae in multiple sclerosis.", "authors": [{"family": "Haghgoy", "given": "Ali", "initials": "A"}, {"family": "F\u00e4llmar", "given": "David", "initials": "D"}, {"family": "Tolf", "given": "Andreas", "initials": "A"}, {"family": "Burman", "given": "Joachim", "initials": "J"}], "type": "journal article", "published": "2026-11-10", "journal": {"title": "Mult Scler Relat Disord", "issn": "2211-0356", "volume": "117", "pages": "108054", "issn-l": null}, "abstract": "Rituximab is widely used off-label for multiple sclerosis (MS) in Sweden, and many centres have transitioned from originator rituximab (MabThera\u00ae) to biosimilars for economic reasons. Evidence on outcomes following a switch to the biosimilar Rixathon\u00ae in MS remains limited.\n\nEffectiveness and safety of rituximab before and after a switch from MabThera\u00ae to Rixathon\u00ae in routine health care.\n\nThis retrospective observational cohort study was conducted at Uppsala University Hospital, Sweden, using prospectively collected data from the Swedish MS Registry and medical records. Patients receiving MabThera\u00ae who switched to Rixathon\u00ae from January 1, 2023 were included if they had follow-up and at least one plasma neurofilament light chain (pNfL) and/or MRI assessment in each treatment period. The primary outcome was pNfL; secondary outcomes included MRI activity, relapses, Expanded Disability Status Scale (EDSS) trajectories, no evidence of disease activity (NEDA), and serious adverse events (CTCAE grade 3-5). Longitudinal outcomes were analysed using mixed-effects models with time centred at the switch. The study was registered at ClinicalTrials.gov (NCT07235644).\n\nThe cohort comprised 136 patients (median age 45 years; 70% women), contributing 1012 pNfL measurements. pNfL decreased during MabThera\u00ae treatment and remained stable at low levels after switching to Rixathon\u00ae, consistent with a transition from treatment initiation to maintenance. Age-adjusted pathological pNfL values occurred in 34/135 (25%) patients during MabThera\u00ae and 16/132 (12%) during Rixathon\u00ae (p = 0.001). Among 773 brain MRI examinations (n = 129), no new or enlarging T2 lesions or gadolinium-enhancing lesions were detected after the switch. Relapse rates were low in both periods, EDSS slopes did not differ significantly, and serious adverse events were uncommon.\n\nIn this real-world MS cohort, switching from MabThera\u00ae to the biosimilar Rixathon\u00ae provided evidence of maintained disease control, with no new safety signal observed during follow-up.", "doi": "10.1016/j.msard.2026.108054", "pmid": "43033548", "labels": {"Bioinformatics (NBIS)": "Service", "Bioinformatics Support and Infrastructure": "Service", "Bioinformatics Support, Infrastructure and Training": "Service"}, "xrefs": [{"db": "pii", "key": "S2211-0348(26)01089-8"}], "notes": [], "created": "2026-11-20T15:08:37.778Z", "modified": "2026-11-20T15:08:37.782Z"}